Alzheimer's Drug Discovery Foundation Seeks Proposals for Early Stage Drug Development Programs

2013 GENERAL REQUEST FOR PROPOSALS (RFP) AND FUNDING PRIORITIES 
The Alzheimer’s Drug Discovery Foundation (ADDF) funds drug discovery and development research
programs in the field of Alzheimer’s disease (AD), related dementias and cognitive aging. The ADDF seeks to fill the critical translational funding gap between basic research and later stage drug development by funding promising drug discovery and development programs. In addition to funding academic programs, the ADDF also invests in and creates early stage biotechnology companies. The ADDF also co-sponsors conferences to stimulate new ideas and approaches in areas of interest to the Foundation.
FUNDING MECHANISMS
 Academic Drug Discovery and Development Program seeks to create and support innovative
translational programs in academic medical centers and universities.

 Biotechnology Development Program supports qualified scientific projects in existing, private,
early-stage biotechnology companies. The ADDF will provide support for qualified projects in more
advanced companies if a clear need for non-profit funding to support the project can be
demonstrated and justified. Funding is typically made as a program-related investment.

 Biotechnology Founders Technology Transfer Program supports academic programs that are
eligible for technology transfer and the start-up of new biotechnology companies. Up to 35% of funds
from these awards may be employed for expenses related to company formation, such as
administrative, legal, patent and third-party vendor costs.

 Conference Grants support innovative scientific conferences that stimulate discussion around novel
targets. 2013 QUARTERLY DEADLINES*
January 22
March 5
June 5
September 5
December 5